Washington University School of Medicine
med.wustl.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,767
Active
357
Phase 3
64
Total enrollment
2,157,068
Pipeline matrix
Showing 40 of 256 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Bupivacaine | — | — | — | 5 | |||
| FluMist | — | — | — | — | — | 1 | |
| inactivated influenza vaccine | — | — | — | — | — | 1 | |
| Zynrelef | — | — | — | — | — | 1 | |
| trivalent inactivated influenza vaccine | — | — | — | — | — | 1 | |
| nonavalent HPV vaccine | — | — | — | — | — | 1 | |
| hepatitis A (HAV) vaccines | — | — | — | — | — | 1 | |
| tetanus, diphtheria and acellular pertussis vaccine | — | — | — | — | — | 1 | |
| Cetuximab | — | — | — | 10 | |||
| Lecanemab | — | — | — | — | — | 3 | |
| Normal saline | — | — | — | — | 5 | ||
| Palbociclib | — | — | — | — | 4 | ||
| Remternetug | — | — | — | — | — | 2 | |
| E2814 | — | — | — | — | — | 2 | |
| Fluvoxamine | — | — | — | — | 5 | ||
| Gantenerumab | — | — | — | — | — | 3 | |
| HFrEF Polypill | — | — | — | — | 2 | ||
| Solanezumab | — | — | — | — | — | 2 | |
| Extracorporeal Photopheresis | — | — | — | — | — | 1 | |
| Buprenorphine Transdermal Matrix Patch | — | — | — | — | — | 1 | |
| Lidocaine | — | — | 4 | ||||
| Nivolumab | — | — | — | — | 16 | ||
| Pembrolizumab | — | — | — | — | 15 | ||
| Cisplatin | — | — | — | 18 | |||
| Carboplatin | — | — | — | — | 16 | ||
| Paclitaxel | — | — | — | — | 14 | ||
| Zanzalintinib | — | — | — | — | 4 | ||
| Gemcitabine | — | — | — | — | 17 | ||
| Temozolomide | — | — | — | 9 | |||
| Ipilimumab | — | — | — | — | 6 | ||
| Durvalumab | — | — | — | — | 6 | ||
| Anastrozole | — | — | — | — | — | 4 | |
| Mosunetuzumab | — | — | — | — | 3 | ||
| Melphalan | — | — | — | 9 | |||
| Irinotecan | — | — | — | — | 9 | ||
| nab-Paclitaxel | — | — | — | — | 8 | ||
| Mycophenolate mofetil | — | — | — | 6 | |||
| Capecitabine | — | — | — | — | 6 | ||
| Carmustine | — | — | — | — | 5 | ||
| Dapagliflozin | — | — | — | 5 |
216 more active programs hidden
Next readouts
- 2020-02-05
- 2021-04-13
- 2021-11-27
- 2022-02-15
- 2022-04-06
- 2022-05-13
- 2022-09-29
- 2023-02-13
- 2024-03-22
- 2024-12-31
Top conditions
- Obesity65
- Breast Cancer49
- Depression37
- Multiple Myeloma36
- Myelodysplastic Syndromes27
- Pancreatic Cancer24
- Parkinson Disease22
- Breast Neoplasms21
Frequently asked questions about Washington University School of Medicine
- How many clinical trials does Washington University School of Medicine have on ClinicalTrials.gov?
- Washington University School of Medicine is listed as the lead sponsor on 1,767 clinical trials in ClinicalTrials.gov, 357 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Washington University School of Medicine's trials are in Phase 3?
- 64 of Washington University School of Medicine's trials are in Phase 3, spread across 256 active drug programs.
- What therapeutic areas does Washington University School of Medicine focus on?
- Washington University School of Medicine's most-studied conditions on ClinicalTrials.gov are Obesity, Breast Cancer, Depression, Multiple Myeloma, Myelodysplastic Syndromes.
- When are Washington University School of Medicine's next clinical trial readouts?
- Washington University School of Medicine has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma”, expected around 2020-02-05.